138 related articles for article (PubMed ID: 21235431)
1. From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.
Curran A; Ribera E
Expert Opin Drug Saf; 2011 May; 10(3):389-406. PubMed ID: 21235431
[TBL] [Abstract][Full Text] [Related]
2. Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
Nolan D; Mallal S
J HIV Ther; 2003 Feb; 8(1):2-6. PubMed ID: 12840707
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
[TBL] [Abstract][Full Text] [Related]
4. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
[TBL] [Abstract][Full Text] [Related]
5. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
[TBL] [Abstract][Full Text] [Related]
6. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
[TBL] [Abstract][Full Text] [Related]
7. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
[TBL] [Abstract][Full Text] [Related]
9. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
Naeger LK; Margot NA; Miller MD
Antimicrob Agents Chemother; 2002 Jul; 46(7):2179-84. PubMed ID: 12069972
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
Venhoff N; Setzer B; Melkaoui K; Walker UA
Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
[TBL] [Abstract][Full Text] [Related]
12. [Tenofovir as a strategy to avoid or limit adverse effects].
Portilla J
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():19-24. PubMed ID: 19195434
[TBL] [Abstract][Full Text] [Related]
13. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Balestre E; Dupon M; Capdepont S; Thiébaut R; Boucher S; Fleury H; Dabis F; Masquelier B;
J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
[TBL] [Abstract][Full Text] [Related]
14. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
McComsey GA; Paulsen DM; Lonergan JT; Hessenthaler SM; Hoppel CL; Williams VC; Fisher RL; Cherry CL; White-Owen C; Thompson KA; Ross ST; Hernandez JE; Ross LL
AIDS; 2005 Jan; 19(1):15-23. PubMed ID: 15627029
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
McGee KC; Shahmanesh M; Boothby M; Nightingale P; Gathercole LL; Tripathi G; Harte AL; Shojaee-Moradie F; Umpleby AM; Das S; Al-Daghri NM; McTernan PG; Tomlinson JW
Antivir Ther; 2012; 17(3):495-507. PubMed ID: 22300946
[TBL] [Abstract][Full Text] [Related]
16. [To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].
Zhou X; Yu W; Li T; Guo F; Lin Q; Shao H; Tian J; Xu Y; Sun P
Zhonghua Nei Ke Za Zhi; 2014 Aug; 53(8):622-5. PubMed ID: 25376824
[TBL] [Abstract][Full Text] [Related]
17. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.
Shlay JC; Sharma S; Peng G; Gibert CL; Grunfeld C
J Acquir Immune Defic Syndr; 2008 May; 48(1):53-62. PubMed ID: 18491421
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments.
Note R; Maisonneuve C; Lettéron P; Peytavin G; Djouadi F; Igoudjil A; Guimont MC; Biour M; Pessayre D; Fromenty B
Antimicrob Agents Chemother; 2003 Nov; 47(11):3384-92. PubMed ID: 14576092
[TBL] [Abstract][Full Text] [Related]
19. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
Njuguna C; Orrell C; Kaplan R; Bekker LG; Wood R; Lawn SD
PLoS One; 2013; 8(5):e63596. PubMed ID: 23717451
[TBL] [Abstract][Full Text] [Related]
20. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T
Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
